HealthEquity, Inc.
92.66USD
-0.7000 (-0.75%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.15▼ | $1.16 | 4 | 5 |
| Next quarter | $1.1▼ | $1.14 | 1 | 10 |
| Current year | $4.72▲ | $4.72 | 5 | 2 |
| Next year | $5.5▲ | $5.48 | 5 | 4 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $1.19 | $1.24 | +0.05 (+3.9%) |
| 2026-04-30 | $1.12 | $1.24 | +0.12 (+11.2%) |
| 2026-01-31 | $0.9 | $0.95 | +0.05 (+5.8%) |
| 2025-10-31 | $0.91 | $1.01 | +0.10 (+10.7%) |
209 ratings from 26 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Deutsche Bank | Maintained | Buy | $135 $142 | Aug 31, 2026 |
| BTIG | Reiterated | Buy | $115 | Aug 28, 2026 |
| BTIG | Maintained | Buy | $110 $115 | Jul 24, 2026 |
| RBC Capital | Reiterated | Outperform | $108 | Jun 3, 2026 |
| Citizens | Maintained | Market Outperform | $110 $111 | Jun 1, 2026 |
| RBC Capital | Maintained | Outperform | $100 $108 | May 29, 2026 |
| Barrington Research | Maintained | Outperform | $110 | May 22, 2026 |
| BMO Capital | Upgraded from Market Perform | Outperform | $85 $105 | Apr 9, 2026 |
| Deutsche Bank | Maintained | Buy | $120 $128 | Mar 19, 2026 |
| Barrington Research | Maintained | Outperform | $125 $110 | Mar 18, 2026 |
| JP Morgan | Maintained | Overweight | $129 $123 | Mar 18, 2026 |
| RBC Capital | Maintained | Outperform | $110 $100 | Mar 18, 2026 |
| Barclays | Maintained | Overweight | $118 $110 | Feb 18, 2026 |
| BTIG | Maintained | Buy | $130 $110 | Feb 17, 2026 |
| Goldman Sachs | Downgraded from Neutral | Sell | $89 | Jan 9, 2026 |
| Keybanc | Maintained | Overweight | $120 $125 | Jan 8, 2026 |
| Barclays | Initiated | Overweight | $118 | Dec 9, 2025 |
| Barrington Research | Maintained | Outperform | $125 | Dec 4, 2025 |
| JP Morgan | Maintained | Overweight | $126 $129 | Dec 4, 2025 |
| Citizens | Maintained | Market Outperform | $117 $122 | Dec 4, 2025 |
| BTIG | Reiterated | Buy | $130 | Dec 4, 2025 |
| BMO Capital | Initiated | Market Perform | $100 | Nov 13, 2025 |
| Keybanc | Maintained | Overweight | $125 $120 | Oct 8, 2025 |
| Jefferies | Maintained | Buy | $130 $134 | Sep 3, 2025 |
| JP Morgan | Maintained | Overweight | $125 $126 | Sep 3, 2025 |
73 filings from 17 insiders · 17 buy / 6 sell over 6m
Officers and directors of HQY, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DILLON ADRIAN TDirector | Sell | 7.6k | $104.47 | $798k | Aug 25, 2026 |
| DILLON ADRIAN TDirector | Exercise | 7.6k | $32.50 | $248k | Aug 25, 2026 |
| FIORE MICHAEL HENRYOfficer | Sell | 2.4k | $95.00 | $224k | Jul 10, 2026 |
| FIORE MICHAEL HENRYOfficer | Sell | 2.5k | $95.00 | $235k | Jul 2, 2026 |
| DILLON ADRIAN TDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| DILSAVER EVELYN SDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| SELANDER ROBERT WDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| NATARAJAN RAJESHDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| PARKER STUART BDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| GASSEN WILLIAMDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| WELLBORN GAYLE FURGURSONDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| MCCOWAN DEBRA CHARLOTTEDirector | Grant | 2.9k | — | — | Jun 25, 2026 |
| FIORE MICHAEL HENRYOfficer | Sell | 3.1k | $95.00 | $298k | May 29, 2026 |
| WELLBORN GAYLE FURGURSONDirector | Exercise | 2.4k | $47.21 | $115k | May 28, 2026 |
| LADD DELANO W IVGeneral Counsel | Sell | 7.5k | $90.00 | $675k | May 28, 2026 |
| WELLBORN GAYLE FURGURSONDirector | Sell | 2.4k | $90.00 | $220k | May 28, 2026 |
| NEELEMAN STEPHENOfficer and Director | Grant | 39.8k | — | — | Mar 25, 2026 |
| ROSNER ELIMELECHChief Technology Officer | Grant | 60.6k | — | — | Mar 25, 2026 |
| FIORE MICHAEL HENRYOfficer | Grant | 17.6k | — | — | Mar 25, 2026 |
| GATHRIGHT MICHAELOfficer | Grant | 15.2k | — | — | Mar 25, 2026 |
No analyst notes on HQY yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 10 | 0 | 0 | 0 | Buy1.67 |
| 1 mo ago | 5 | 10 | 0 | 0 | 0 | Buy1.67 |
| 2 mo ago | 5 | 10 | 0 | 0 | 0 | Buy1.67 |
| 3 mo ago | 5 | 10 | 0 | 1 | 0 | Buy1.81 |